An international trial across 11 countries tested amivantamab in patients with advanced or recurrent cancer that had spread and failed prior treatments. The injection shrank tumors in more than a third of participants, with dramatic changes within weeks. In 15 patients, tumors disappeared completely. Among 102 head and neck cancer patients, 43 had tumor shrinkage or disappearance, including 28 with significant shrinkage and 15 with eradication. Similar results were reported in lung cancer patients. Amivantamab targets EGFR and MET and helps activate the immune system, and it is being evaluated in about 60 clinical trials for multiple cancer types.
"These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]